Listen and follow our podcasts on:

Bayer

Podcast 1: Upper GI

Dr Efrat Dotan and Dr Nataliya Uboha focus on their selected key abstracts in upper GI cancer, sharing their thoughts on how the data could influence the treatment and management of gastric/gastro-esophageal (G/GE) cancer.

Clinical takeaways: 

  • SPOTLIGHT trial results demonstrate the benefit of treatment with zolbetuximab + mFOLFOX in patients expressing Claudin 18.2  
  • In RATIONALE 305, tislelizumab, like nivolumab, shows promising results for PD-L1+ve patients
  • CheckMate 649 follow up data at 3 years further supports the use of nivolumab + chemotherapy in first-line setting in patients with advanced G/GE cancer
  • INTEGRATE IIa study had statistically significant results for regorafenib vs placebo in refractory advanced GE cancer. Results of INTEGRATE IIb are eagerly awaited 
  • The data from NEO-AEGIS make clinical decision-making between peri-operative chemotherapy and CROSS easier
  • The results from INFINITY show the potential of tremelimumab + durvalumab as standard of care for patients with resectable MSI-H G/GE cancer

 

Podcast 2: Lower GI 

Prof. Shubham Pant and Prof. Andrea Sartore-Bianchi discuss lower GI cancer and the key abstracts that they identified as potentially impacting the way we manage treatment for colorectal cancer (CRC).

Clinical takeaways:

  • In SUNLIGHT, trifluridine/tipiracil plus bevacizumab improved overall survival and progression-free survival in refractory CRC patients and should be considered a standard of care in the refractory treatment setting
  • In the kinetics of postoperative cfDNA/ctDNA2 study, post operative ctDNA-positivity was significantly associated with shorter recurrence-free survival. Clinical data are insufficient at this stage to consider molecular residual disease testing as standard of care for patients with resectable CRC
  • Durable objective responses were observed in heavily pre-treated MSS CRC patients treated with balstilimab plus botensilimab. Further investigation is warranted
  • In NRG-GI002, neither veliparib or pembrolizumab significantly improved short-term outcomes in unselected patients when added to total neoadjuvant therapy (TNT). This trial provides TNT outcome data for benchmarking in future LARC trials

 

Listen to the podcasts and download the slides on the selected abstracts.

 

Prof. Efrat Dotan is the executive medical director for Penn Medicine Ann B. Barshinger Cancer Institute in Lancaster, Pennsylvania. She graduated from the Technion Institute of Technology Medical School in Israel and moved to the US to pursue her specialized training. She completed her residency at Lenox Hill Hospital in New York, and her hematology/oncology fellowship at Fox Chase Cancer Center. Prof. Dotan specializes in the management of patients with gastrointestinal malignancies, specifically pancreatic cancer. Her research interest is in development of new treatment options for patients with gastrointestinal cancers. She is the PI for multiple clinical trials in this arena. Prof. Dotan is a member of the Gastrointestinal Malignancies Committee of the Eastern Cooperative Oncology Group (ECOG), serves as the PI for multiple studies and is co-chair of the NCI pancreatic task force. Dr Dotan’s other interest is in the management of older patients with cancer, developing treatment strategies and tools to improve the care of this patient population. She has led multiple research projects evaluating the care of older patients with gastrointestinal malignancies. She is a senior member of the Cancer and Aging Research Group, the chair of the Older Adult Oncology Guidelines for NCCN and the chair of the geriatric oncology working group for ECOG.

Prof. Efrat Dotan has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Agenus, Amgen, Ipsen, Merck, MERUS, Olympus, Pfizer, TME Biopharmaceuticals

Dr Nataliya Uboha is an Associate Professor at the University of Wisconsin, Department of Medicine, Division of Hematology and Oncology and a member of Carbone Cancer Center (UWCCC). Her clinical and research activities focus on upper GI cancers. She has extensive clinical trial experience, with a particular emphasis on phase 1 and biomarker based clinical studies. She is a Faculty Leader for the Cancer Therapy Discovery & Development (Phase I) Program at UWCCC. She is a co-leader and founder of the Basket Disease Oriented Team at UWCCC, which has a specific focus on biomarker based trials across disease types. Dr Uboha has a number of regional and national leadership roles. She serves on the board of Wisconsin Association of Hematology and Oncology. She is a co-chair for the GI Cancer Research Group in Big 10 Cancer Research Consortium. She chairs the Upper GI working group at ECOG-ACRIN and serves on the National Cancer Institute Upper GI Taskforce as an ECOG representative.

Dr Nataliya Uboha has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Consulting: QED, Taiho Inc., Incyte, AstraZeneca, Pfizer, Boston Gene, Helsinn
Research Funding: Taiho Inc, Ipsen, EMD Serono
Long position holdings: Natera, Exact Sciences

Dr. Shubham Pant is a Professor in the Department of Gastrointestinal (GI) Medical Oncology with a joint appointment in the Department of Investigational Cancer Therapeutics (Phase I Center) at The University of Texas MD Anderson Cancer Center. Dr. Pant is recognised as an international expert in GI cancers with an emphasis on pancreatic and biliary cancers and Phase 1 trials.

 

Dr. Pant's research focuses on novel immunotherapeutic approaches and targeted therapies in GI cancers, including devising novel ways to target the KRAS mutation. He has been the lead/co-lead of several global practice-changing studies, including 'Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicenter, single-arm, phase 2b study'; 'Adagrasib in advanced solid tumors harboring a KRASG12C mutation' and 'Erdafitinib in patients with advanced solid tumors with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study'; amongst others. He has over 100 peer-reviewed publications and has published in high-impact journals, including The Lancet, Lancet Oncology, and Journal of Clinical Oncology. He is frequently invited to present his research at national and international meetings. He collaborates on numerous grants, including R01 and SPORE grants funded by the National Institute of Health. Dr. Pant serves on the National Cancer Institute (NCI) Pancreas Task Force and the Pancreatic Cancer Action Network's (PanCan) Scientific and Medical Advisory Board. He also helped draft the American Society of Clinical Oncology (ASCO) Metastatic Pancreatic Cancer Guidelines, which provide evidence-based recommendations for physicians. He is also the editor of the book Pancreatic Cancer: Current Therapeutics and Future Directions (Publisher: Springer).

Prof. Shubham Pant has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Alligator Bioscience, Amal Therapeutics, Arcus, AskGene Pharma, Astellas, AstraZeneca, BioNTech, Boehringer Ingelheim, BPGBio, Bristol-Myers Squibb, Elicio, Framewave, Immuneering, ImmunoMET, Ipsen, Janssen, Jazz, Lilly, Mirati Therapeutics, NGM Pharmaceuticals, Nihon Medi-Physics Co, Ltd, Novartis, Pfizer, Revolution Medicine, Theriva Biosciences, USWorldmeds, Zymeworks

Andrea Sartore-Bianchi is the Director of the Division of Clinical Research and Innovation at Grande Ospedale Metropolitano Niguarda in Milano, Italy, and Associate Professor of Oncology at the University of Milano. He received his MD and postgraduate degree in Oncology at the University of Pavia, Italy, and subsequently conducted preclinical research at Brown University, Providence, RI, USA.

 

His main clinical and research interests include precision oncology and the treatment of gastrointestinal cancers, particularly colorectal carcinomas, focusing on biomarkers of sensitivity/resistance to targeted therapies. He is principal and co-investigator in Phase I-III clinical trials for solid tumours and carried out initial studies paving the way for the use of RAS and Her2 as tumor tissue/ctDNA biomarkers in colorectal cancer. He has published 200 peer-reviewed articles in various medical journals with a H-index of 62 (Scopus).

Prof. Andrea Sartore-Bianchi has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Amgen, Bayer, Sanofi and Servier Pharmaceuticals. 

Programme summary
Listen to the podcast now
Other episodes of this series
Update from ASCO GI 2023

Update from ASCO GI 2023

Episode 1: Upper GI cancer highlights

Current Episode
Update from ASCO GI 2023

Update from ASCO GI 2023

Episode 2: Lower GI highlights

Share this programme
This educational programme is supported by an Independent Educational Grant from Bayer
Supporter Acknowledgement
This educational programme is supported by an Independent Educational Grant from Bayer
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
GI CONNECT

GI CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from Bayer, Ipsen, BeiGene Europe and Pierre Fabre Laboratories.  

Meet the experts Independent IME approved

Other programmes of interest

conference-update Conference update
Oncology 
Highlights from ASCO 2025

Coming Soon: Expert insights on the latest data 

Experts
Prof. Mark Socinski, Dr Elizabeth Smyth, Dr Paolo Tarantino, Dr Domenica Lorusso, Prof. Gerhardt Attard
Endorsed by
Exon20group Biomarker Collaborative ICAN international cancer advocacy network
Lung Cancer Europe
  • clock 1 MIN
  • calendar May 2025

The oncogene-addicted NSCLC supported through an Independent Educational Grant from Bayer with all other updates supported by COR2ED
symposium Symposium
Oncology 
ER+/HER2- metastatic breast cancer: Highlights from ESMO Breast Cancer 2025 Satellite Symposium

Medical experts discuss treatment strategies and sequencing after ET + CDK4/6i for ER+/HER2- metastatic breast cancer

Experts
Prof. Wolfgang Janni, Prof. Sherko Kümmel, Prof. Michail Ignatiadis
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar May 2025

This programme has been sponsored by Menarini Stemline and is intended for healthcare professionals only
podcast Podcast
Hemostasis and bleeding disorders Oncology 
Serie de podcasturi referitoare la gestionarea trombozei

Experți de renume din domeniul medical își împărtășesc perspectivele. Navigați în secțiuni pentru a selecta un episod al podcastului 

Experts
Prof. Dimitrios Tsakiris, Dr Lars Asmis, Prof. Jerzy Windyga, Prof. Daniel Bolliger
  • download Downloadable
    Resources
  • clock 21 MIN
  • calendar May 2025

This educational programme is supported by an Independent Educational Grant from Viatris.
video Video
Oncology Hemato-oncology 
Optimising the sequence of novel therapies from early relapse in multiple myeloma

Improving the survival of patients with relapsed/refractory multiple myeloma

Experts
Prof. Hermann Einsele, Prof. Evangelos Terpos
  • download Downloadable
    Resources
  • clock 2 MIN
  • calendar May 2025

This programme has been sponsored by Menarini Stemline and is intended for healthcare professionals only
animated-video Animated Video
Oncology 
BRAF V600E mutated NSCLC: The evolving treatment landscape

Expert insights into personalised treatment strategies in BRAF-mutated NSCLC

Experts
Prof. Amanda Tufman
Endorsed by
BRAF Bombers ICAN international cancer advocacy network Biomarker Collaborative
Lung Cancer Europe
  • download Downloadable
    Resources
  • clock 6 MIN
  • calendar May 2025

This content is intended for HCPs outside the UK & ROI only. The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution. This programme is supported by an Independent Educational Grant from Pierre Fabre Laboratories.  The programme is, therefore, independent; the content is not influenced by Pierre Fabre Laboratories and is under the sole responsibility of the experts. 
podcast Podcast
Oncology 
Tackling metastatic pancreatic ductal adenocarcinoma (mPDAC)

Chemotherapy strategies that matter

Experts
Prof. Shubham Pant, Prof. Efrat Dotan
Endorsed by
DiCE ICAN international cancer advocacy network
  • download Downloadable
    Resources
  • clock 4 MIN
  • calendar May 2025

Educational programme supported by an Independent Educational Grant from Ipsen USA